drugset / Trial / NCT00299208

Azithromycin Combination Therapy for Malaria

NCT00299208

RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this study is to develop a safe, well tolerated, and highly efficacious azithromycin combination treatment for uncomplicated falciparum malaria. Azithromycin is a drug that has shown potential for malaria treatment. It will be combined with other malaria drugs currently approved for treatment in Thailand. About 120 people, ages 20-65, will be enrolled in Thailand. Participants will have severe cases of malaria and they will be hospitalized 28 days for treatment.

Timeline

Start
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 100 mg
Subject Artesunate Small molecule 200 mg
Subject Azithromycin Small molecule 500 mg
Subject Azithromycin Small molecule 750 mg
Subject Azithromycin Small molecule 1000 mg
Subject Quinine Small molecule 10 mg/kg